Gait speed and neurocognition among older people with and without HIV - PubMed (original) (raw)
. 2025 Dec 1;39(15):2191-2199.
doi: 10.1097/QAD.0000000000004312. Epub 2025 Jul 30.
Raymond Jones 2, Crystal X Wang 3, Casey D Xavier Hall 4 5, Jun Y Byun 6, Kristen D Krause 7, Maulika Kohli 8, Kristine M Erlandson 9, Erin E Sundermann 3, David J Moore 3, Scott Letendre 3 10, Ronald J Ellis 3 11
Affiliations
- PMID: 40779506
- PMCID: PMC12440577
- DOI: 10.1097/QAD.0000000000004312
Gait speed and neurocognition among older people with and without HIV
Evelyn Iriarte et al. AIDS. 2025.
Abstract
Objective: Examine the associations of gait speed with global and domain-specific neurocognition in older people with HIV (PWH) versus people without HIV (PWoH).
Methods: Participants included 285 PWH and 214 PWoH 50 years and older (Mage = 60.1, SD age = 7.1) who completed a gait examination and a comprehensive neurocognitive assessment.
Results: Gait speed was significantly slower in PWH ( M = 3.3 s, SD = 1.1) than PWoH ( M = 3.0 s, SD = 0.9; P = 0.006). Slower gait speed was significantly associated with poorer global neurocognition ( β = -0.17, P = 0.009) and deficits in multiple neurocognitive domains, including verbal fluency, executive functioning, processing speed, and motor skills, after adjusting for sociodemographic, HIV-related, and medical characteristics in PWH. A significant interaction between gait speed and HIV status emerged for verbal fluency, suggesting differential cognitive impacts ( β = -0.45, P = 0.008).
Conclusions: Our findings highlight nuanced relationships between gait speed and neurocognition, emphasizing the need for longitudinal research to establish causal mechanisms and potential clinical screening approaches.
Keywords: HIV; aging; gait speed; neurocognition.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflict of interest: none.
References
- Centers for Disease Control and Prevention. Diagnoses, deaths, and prevalence of HIV in the United States and 6 territories and freely associated states, 2022. HIV Surveillance Report, 2022; 2024.
- Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010. Dec 7;75(23):2087–96. -PMC -PubMed
MeSH terms
Grants and funding
- R25 MH108389/MH/NIMH NIH HHS/United States
- K01 AG086063/AG/NIA NIH HHS/United States
- L60 HL170367/HL/NHLBI NIH HHS/United States
- T32 DA031098/DA/NIDA NIH HHS/United States
- P30 MH062512/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical